Illumina Ventures, a San Francisco, CA-based genomics and precision health venture firm, has launched Illumina Ventures Labs.
Building on the foundation of the Illumina Accelerator program, Illumina Ventures Labs will operate and provide access to fully equipped genomics labs in the US and the UK, mentorship, and seed financing to attract a broad range of genomics related start-ups. Illumina, Inc. will provide startups with technical guidance from its subject matter experts and will provide Illumina Ventures Labs access to its next-generation sequencing (NGS) platforms, in lieu of operating its Accelerator program.
Led by Nick Naclerio, Founding Partner, Illumina Ventures is an independently managed, healthcare-focused venture firm in a strategic partnership with Illumina (NASDAQ: ILMN). As an early-stage, value-add investor, Illumina Ventures helps entrepreneurs develop breakthrough science and technologies into market-leading companies to transform healthcare. The firm focuses on investment in life science tools, therapeutics, diagnostics, personal wellness and sustainability. To learn more, visit .
Since 2016, Illumina Ventures has invested in over 30 startups in the US and Europe, making it one of the leading investors in life science tools, clinical diagnostics, and genomics-enabled therapeutic platforms. While Illumina is an anchor limited partner in the fund, the majority of the $560M raised by the independently managed firm comes from other limited partners.
FinSMEs
21/06/2023